Jeremy R. Graff
YOU?
Author Swipe
View article: Data from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
Data from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity Open
p38α mitogen-activated protein kinase (MAPK) is activated in cancer cells in response to environmental factors, oncogenic stress, radiation, and chemotherapy. p38α MAPK phosphorylates a number of substrates, including MAPKAP-K2 (MK2), and …
View article: Supplementary Figure 2 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
Supplementary Figure 2 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity Open
PDF file - 90K, shRNA silencing of p38a MAPK in U-87MG glioma (Westerns and xenograft tumor growth data).
View article: Supplementary Figure 1 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
Supplementary Figure 1 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity Open
PDF file - 43K, Effect of LY2228820 on MK2 phosphorylation in mouse peripheral blood mononuclear cells (PBMC) and from patients with multiple myeloma.
View article: Supplementary Figure 2 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
Supplementary Figure 2 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity Open
PDF file - 90K, shRNA silencing of p38a MAPK in U-87MG glioma (Westerns and xenograft tumor growth data).
View article: Supplementary Figure 1 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
Supplementary Figure 1 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity Open
PDF file - 43K, Effect of LY2228820 on MK2 phosphorylation in mouse peripheral blood mononuclear cells (PBMC) and from patients with multiple myeloma.
View article: Supplementary Methods, Table 1 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
Supplementary Methods, Table 1 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity Open
PDF file - 86K, Supplemental Table 1. Kinases where LY2228820 shows >1000-fold selectivity in vitro (p38 MAPK vs. other kinase).
View article: Data from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
Data from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity Open
p38α mitogen-activated protein kinase (MAPK) is activated in cancer cells in response to environmental factors, oncogenic stress, radiation, and chemotherapy. p38α MAPK phosphorylates a number of substrates, including MAPKAP-K2 (MK2), and …
View article: Supplementary Methods, Table 1 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
Supplementary Methods, Table 1 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity Open
PDF file - 86K, Supplemental Table 1. Kinases where LY2228820 shows >1000-fold selectivity in vitro (p38 MAPK vs. other kinase).
View article: Supplementary Table 1 from eIF4E Activation Is Commonly Elevated in Advanced Human Prostate Cancers and Significantly Related to Reduced Patient Survival
Supplementary Table 1 from eIF4E Activation Is Commonly Elevated in Advanced Human Prostate Cancers and Significantly Related to Reduced Patient Survival Open
Supplementary Table 1 from eIF4E Activation Is Commonly Elevated in Advanced Human Prostate Cancers and Significantly Related to Reduced Patient Survival
View article: Data from eIF4E Activation Is Commonly Elevated in Advanced Human Prostate Cancers and Significantly Related to Reduced Patient Survival
Data from eIF4E Activation Is Commonly Elevated in Advanced Human Prostate Cancers and Significantly Related to Reduced Patient Survival Open
Elevated eukaryotic translation initiation factor 4E (eIF4E) function induces malignancy in experimental models by selectively enhancing translation of key malignancy-related mRNAs (c-myc and BCL-2). eIF4E activation may reflect increased …
View article: Supplementary Table 1 from eIF4E Activation Is Commonly Elevated in Advanced Human Prostate Cancers and Significantly Related to Reduced Patient Survival
Supplementary Table 1 from eIF4E Activation Is Commonly Elevated in Advanced Human Prostate Cancers and Significantly Related to Reduced Patient Survival Open
Supplementary Table 1 from eIF4E Activation Is Commonly Elevated in Advanced Human Prostate Cancers and Significantly Related to Reduced Patient Survival
View article: Data from eIF4E Activation Is Commonly Elevated in Advanced Human Prostate Cancers and Significantly Related to Reduced Patient Survival
Data from eIF4E Activation Is Commonly Elevated in Advanced Human Prostate Cancers and Significantly Related to Reduced Patient Survival Open
Elevated eukaryotic translation initiation factor 4E (eIF4E) function induces malignancy in experimental models by selectively enhancing translation of key malignancy-related mRNAs (c-myc and BCL-2). eIF4E activation may reflect increased …
View article: 913 Translational analysis of advanced metastatic bladder cancer patients treated with IO combination maveropepimut-S, cyclophosphamide, and pembrolizumab
913 Translational analysis of advanced metastatic bladder cancer patients treated with IO combination maveropepimut-S, cyclophosphamide, and pembrolizumab Open
Background Maveropepimut-S (MVP-S, formerly DPX-Survivac) is comprised of immunogenic T cell peptides from the cancer antigen, survivin, as well as a universal T helper peptide, A16L, and the innate immune activator, poly-dIdC, packed with…
View article: 646 Neoadjuvant immunotherapy combining maveropepimut-S (MVP-S) with letrozole decreases Ki67 and increases Th1 immune response in hormone receptor positive (HR+) early-stage breast cancer (ESBC)
646 Neoadjuvant immunotherapy combining maveropepimut-S (MVP-S) with letrozole decreases Ki67 and increases Th1 immune response in hormone receptor positive (HR+) early-stage breast cancer (ESBC) Open
Background HR+ ESBC is associated with a suboptimal pathologic complete response rate (pCR, ~10%) following neoadjuvant cytotoxic chemotherapy. A genomic analysis among Ki67-high HR+ tumors identified 8-fold upregulation of BIRC5 (survivin…
View article: 1336 DPX-based immune education recruits and activates unique subsets of antigen presenting cells to drive immunogenicity of peptide antigens
1336 DPX-based immune education recruits and activates unique subsets of antigen presenting cells to drive immunogenicity of peptide antigens Open
Background For peptide-based cancer vaccines, successful eradication of tumors relies on the effective and persistent delivery of antigenic peptides to antigen presenting cells (APCs) to prime potent antigen-specific, cytotoxic T cells. Pe…
View article: Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies
Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies Open
Imprime PGG (Imprime) is in late-stage clinical development as a combinatorial agent with several therapeutic modalities. Here we present pre-clinical mechanistic data supportive of Imprime, a soluble yeast β-1,3/1,6-glucan pathogen-associ…
View article: P862 Clinical benefit potentially evident with immunopharmacodynamic responses in prior-checkpoint failed metastatic melanoma patients treated with imprime PGG and pembrolizumab
P862 Clinical benefit potentially evident with immunopharmacodynamic responses in prior-checkpoint failed metastatic melanoma patients treated with imprime PGG and pembrolizumab Open
Background Checkpoint inhibitor (CPI) monotherapy has revolutionized the treatment of melanoma, yet most patients are primary nonresponders or develop secondary resistance. Lack of antigen-specific T cell priming and/or immunosuppressive m…
View article: Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor
Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor Open
Transforming growth factor-β (TGFβ) is an important driver of tumor growth via intrinsic and extrinsic mechanisms, and is therefore an attractive target for developing cancer therapeutics. Using preclinical models, we characterized the ant…
View article: Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation
Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation Open
Imprime PGG (Imprime), an intravenously-administered, soluble β-glucan, has shown compelling efficacy in multiple phase 2 clinical trials with tumor targeting or anti-angiogenic antibodies. Mechanistically, Imprime acts as pathogen-associa…
View article: Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers
Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers Open
Neurofibromin 1-mutant (NF1-mutant) cancers are driven by excessive Ras signaling; however, there are currently no effective therapies for these or other Ras-dependent tumors. While combined MEK and mTORC1 suppression causes regression of …
View article: Phosphorylation of eIF4E serine 209 is associated with tumour progression and reduced survival in malignant melanoma
Phosphorylation of eIF4E serine 209 is associated with tumour progression and reduced survival in malignant melanoma Open
View article: Imprime PGG, an innate immunomodulator for cancer immunotherapy has the potential to modulate macrophages in the tumor and the spleen to an anti-tumor M1-like phenotype
Imprime PGG, an innate immunomodulator for cancer immunotherapy has the potential to modulate macrophages in the tumor and the spleen to an anti-tumor M1-like phenotype Open
Meeting abstracts Imprime PGG (Imprime) in combination with anti-VEGF monoclonal antibody, bevacizumab has shown promising clinical efficacy in randomized Phase II clinical trials in non-small cell lung cancer (NSCLC) patients. Imprime, a …
View article: Antisense oligonucleotide targeting eukaryotic translation initiation factor 4E reduces growth and enhances chemosensitivity of non-small-cell lung cancer cells
Antisense oligonucleotide targeting eukaryotic translation initiation factor 4E reduces growth and enhances chemosensitivity of non-small-cell lung cancer cells Open
View article: Targeting the eIF4F Translation Initiation Complex: A Critical Nexus for Cancer Development
Targeting the eIF4F Translation Initiation Complex: A Critical Nexus for Cancer Development Open
Elevated protein synthesis is an important feature of many cancer cells and often arises as a consequence of increased signaling flux channeled to eukaryotic initiation factor 4F (eIF4F), the key regulator of the mRNA–ribosome recruitment …